Exchange: OTC·Updated 03:58 PM EST

CRLBF News

News
all
press releases
Cresco Labs Inc. (CRLBF) Reports Q3 Loss, Misses Revenue Estimates
Cresco Labs Inc. (CRLBF) delivered earnings and revenue surprises of -50.00% and -0.54%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Cresco Labs Inc. (CRLBF) Reports Q3 Loss, Misses Revenue Estimates
Cresco Labs Inc. (CRLBF) delivered earnings and revenue surprises of -50.00% and -0.54%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Aurora Cannabis (ACB) delivered earnings and revenue surprises of +200.00% and +17.21%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Perrigo (PRGO) delivered earnings and revenue surprises of +7.14% and -0.19%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Haemonetics (HAE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
Cresco's 10% monthly rally reflects stronger revenues, organic growth and margins, but competition and normalization risks cloud the outlook.
Zacks
Cresco Labs Inc. (CRLBF) delivered earnings and revenue surprises of +300.00% and +4.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Green Thumb has surged 17.5% in three months as regulatory progress, Q1 growth and buybacks lift sentiment, but competition and pricing pressure persist.
Zacks
CRLBF is down 28.5% YTD as revenue pressure and competition persist, but retail expansion and improving estimates could shape its next move.
Zacks
The cannabis ETF has surged 104% over the past year, outperforming both the North American Marijuana Index and the S&P 500.
Stocktwits
Cresco Labs Inc. (CRLBF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks

Advertisement|Remove ads.